Drugs / RSV preF protein
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03502707 | Jul 2018 → May 2022 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04453202 | Jul → Sep 2020 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV preF protein | “A combination vaccine containing Ad26.RSV.preF and purified recombinant RSV preF protein has previously demonstrated efficacy and tolerability in older adults.” PMID 39276619 ↗ Sep 2024 |
| Modality | Protein / enzyme biologic | “Addition of recombinant RSV preF protein might enhance RSV-specific humoral immune responses, especially in older populations.” PMID 37433021 ↗ Jan 2024 |
| Route | Intramuscular | “intramuscular injection” NCT03502707 ↗ |